Article
Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.
Future oncology (London, England) - 1 Jan 2015
de Marinis Filippo, Vergnenegre Alain, Passaro Antonio, Dubos-Arvis Catherine, Carcereny Enric, Drozdowskyj Ana, Zeaiter Ali, Perez-Moreno Pablo, Rosell Rafael
Abstract excerpt
AIM: This analysis investigates incidence and time course of rash in the EURTAC study. MATERIALS & METHODS: Patients with EGFR mutation-positive non-small-cell lung cancer were randomized 1:1 to receive once daily erlotinib or 3-weekly cycles of chemotherapy. RESULTS: Of the 86 erlotinib-treated patients, 71 reported rash. Median time to first rash appearance was 0.7 months. Most patients (n = 65) had the same or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.